Nvidia is using its extraordinary cash generation to buy stakes in companies that may also become customers. The latest reported commitments include minority investments in French health platform Doctolib, robotics developer Genesis AI, software company Pigment and materials startup Entalpic. Terms were not disclosed.
The transactions are individually small compared with Nvidia's cash flow, but the portfolio around them is no longer small. TIKR reported that Nvidia's long-term investments reached $51.16 billion at the end of July 2026, up from $3.80 billion a year earlier. That increase includes valuation changes as well as new cash, so it should not be read as $47 billion of fresh spending.
A strategic flywheel with accounting exposure
The commercial logic is straightforward. Nvidia can help young AI companies finance computing capacity, encourage development on its software stack and share in the upside if those businesses grow. A successful portfolio company can produce both investment gains and future demand for Nvidia hardware.
The risk is that the same relationship can concentrate exposure. Private-company stakes are harder to value than listed securities, and markdowns or impairments can move other income. If a funded company later cuts spending, Nvidia could face an investment loss and weaker chip demand at the same time.
Nvidia's August quarterly filing warned that additional public and non-marketable equity investments could materially affect the carrying value of its holdings. The filing does not identify each new French stake or disclose purchase prices, limiting any deal-level return analysis.
What the next filings must show
The most useful numbers are not press-release counts of portfolio companies. Investors should track cash invested, unrealized gains and losses, impairment charges and the share of investee revenue that depends on Nvidia-backed financing.
Nvidia has ample financial capacity: it reported $96.2 billion of fiscal second-quarter 2027 revenue, up 106% from a year earlier. The strategic portfolio is therefore not a near-term liquidity threat. It is becoming a meaningful capital-allocation line that deserves the same scrutiny as buybacks, research spending and acquisitions.